BioCentury
ARTICLE | Company News

Astellas sales and marketing update

July 22, 2013 7:00 AM UTC

Astellas launched Xtandi enzalutamide in the U.K. to treat metastatic castration-resistant prostate cancer (CRPC) in patients previously treated with docetaxel. The product is available through the U...